Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a biotech firm focusing on innovative drug delivery, is set to present promising data on its osteoarthritis knee treatment, EP-104IAR, at the OARSI World Congress 2024 in Vienna. The company’s treatment showed significant pain reduction and a strong safety profile in a Phase 2b study, potentially marking a major advancement in managing osteoarthritis, particularly for diabetic patients.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
